These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36744183)

  • 21. Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion.
    Li G; Huang R; Fan W; Wang D; Wu F; Zeng F; Yu M; Zhai Y; Chang Y; Pan C; Jiang T; Yan W; Wang H; Zhang W
    Front Immunol; 2021; 12():800928. PubMed ID: 34956239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Static
    Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J
    Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiomics-Based Method for Predicting the Glioma Subtype as Defined by Tumor Grade, IDH Mutation, and 1p/19q Codeletion.
    Li Y; Ammari S; Lawrance L; Quillent A; Assi T; Lassau N; Chouzenoux E
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
    Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
    J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon gamma-related gene signature based on anti-tumor immunity predicts glioma patient prognosis.
    Zhang Z; Shen X; Tan Z; Mei Y; Lu T; Ji Y; Cheng S; Xu Y; Wang Z; Liu X; He W; Chen Z; Chen S; Lv Q
    Front Genet; 2022; 13():1053263. PubMed ID: 36712869
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical prognostic value of isocitrate dehydrogenase mutation, O-6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in glioma patients.
    Chen X; Yan Y; Zhou J; Huo L; Qian L; Zeng S; Li Z; Wei J; Xu Z; Gong Z
    Ann Transl Med; 2019 Oct; 7(20):541. PubMed ID: 31807523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MRI and CT Identify Isocitrate Dehydrogenase
    Patel SH; Batchala PP; Mrachek EKS; Lopes MS; Schiff D; Fadul CE; Patrie JT; Jain R; Druzgal TJ; Williams ES
    Radiology; 2020 Jan; 294(1):160-167. PubMed ID: 31714193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.
    Yang S; Yuan Y; Ren W; Wang H; Zhao Z; Zhao H; Zhao Q; Chen X; Jiang X; Zhang L
    Front Oncol; 2022; 12():1004324. PubMed ID: 36465369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas.
    Yamauchi T; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Kitagawa Y; Kondo E; Tsushita N; Satomi K; Yoshida A; Ichimura K; Narita Y
    Brain Tumor Pathol; 2018 Jul; 35(3):148-158. PubMed ID: 29922974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CDC42-A promising immune-related target in glioma.
    Jiang T; Wang X; Huang J; Chen D
    Front Neurosci; 2023; 17():1192766. PubMed ID: 37476838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
    Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
    Front Neurol; 2022; 13():977180. PubMed ID: 36353126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas.
    Suzuki K; Kawai N; Ogawa T; Miyake K; Shinomiya A; Yamamoto Y; Nishiyama Y; Tamiya T
    EJNMMI Res; 2021 Jul; 11(1):67. PubMed ID: 34291337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas.
    Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J
    Front Oncol; 2021; 11():611038. PubMed ID: 33937022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LGALS3 Is a Poor Prognostic Factor in Diffusely Infiltrating Gliomas and Is Closely Correlated With CD163+ Tumor-Associated Macrophages.
    Hu WM; Yang YZ; Zhang TZ; Qin CF; Li XN
    Front Med (Lausanne); 2020; 7():182. PubMed ID: 32528967
    [No Abstract]   [Full Text] [Related]  

  • 35. Association of IDH mutation and 1p19q co-deletion with tumor immune microenvironment in lower-grade glioma.
    Lin W; Qiu X; Sun P; Ye Y; Huang Q; Kong L; Lu JJ
    Mol Ther Oncolytics; 2021 Jun; 21():288-302. PubMed ID: 34141867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RUNX1/CD44 axis regulates the proliferation, migration, and immunotherapy of gliomas: A single-cell sequencing analysis.
    Zhang H; Cao H; Luo H; Zhang N; Wang Z; Dai Z; Wu W; Liu G; Xie Z; Cheng Q; Cheng Y
    Front Immunol; 2023; 14():1086280. PubMed ID: 36776876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.
    Sabha N; Knobbe CB; Maganti M; Al Omar S; Bernstein M; Cairns R; Çako B; von Deimling A; Capper D; Mak TW; Kiehl TR; Carvalho P; Garrett E; Perry A; Zadeh G; Guha A; Sidney Croul
    Neuro Oncol; 2014 Jul; 16(7):914-23. PubMed ID: 24470545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CEST MRI provides amide/amine surrogate biomarkers for treatment-naïve glioma sub-typing.
    Mancini L; Casagranda S; Gautier G; Peter P; Lopez B; Thorne L; McEvoy A; Miserocchi A; Samandouras G; Kitchen N; Brandner S; De Vita E; Torrealdea F; Rega M; Schmitt B; Liebig P; Sanverdi E; Golay X; Bisdas S
    Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2377-2391. PubMed ID: 35029738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of 1p/19q codeletion status on extent of resection in WHO grade II glioma: Insights from a national cancer registry.
    Lu VM; Alvi MA; Bydon M; Quinones-Hinojosa A; Chaichana KL
    Clin Neurol Neurosurg; 2019 Jul; 182():32-36. PubMed ID: 31063969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.